T
This biotechnology company is developing a pre-clinical therapeutic candidate that sequesters lipotoxic products to treat non-alcoholic steatohepatitis (NASH) and Type 2 diabetes. By targeting these conditions, the company aims to prevent chronic liver disease and improve patient health outcomes.
McLean, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This biotechnology company is developing a pre-clinical therapeutic candidate that sequesters lipotoxic products to treat non-alcoholic steatohepatitis (NASH) and Type 2 diabetes. By targeting these conditions, the company aims to prevent chronic liver disease and improve patient health outcomes.